Smith Shellnut Wilson’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
$295K Buy
3,517
+478
+16% +$39.4K 0.11% 112
2025
Q2
$241K Hold
3,039
0.1% 120
2025
Q1
$273K Hold
3,039
0.13% 115
2024
Q4
$302K Hold
3,039
0.13% 106
2024
Q3
$345K Sell
3,039
-200
-6% -$23.8K 0.16% 100
2024
Q2
$401K Hold
3,239
0.19% 83
2024
Q1
$427K Sell
3,239
-200
-6% -$24.7K 0.23% 80
2023
Q4
$375K Hold
3,439
0.22% 84
2023
Q3
$354K Hold
3,439
0.22% 80
2023
Q2
$397K Sell
3,439
-110
-3% -$12.5K 0.22% 78
2023
Q1
$378K Hold
3,549
0.23% 75
2022
Q4
$394K Hold
3,549
0.24% 72
2022
Q3
$306K Hold
3,549
0.2% 84
2022
Q2
$324K Hold
3,549
0.2% 91
2022
Q1
$291K Sell
3,549
-1,148
-24% -$90.5K 0.15% 115
2021
Q4
$360K Buy
4,697
+758
+19% +$60.4K 0.18% 107
2021
Q3
$296K Buy
3,939
+1,252
+47% +$95.2K 0.17% 110
2021
Q2
$209K Sell
2,687
-129
-5% -$9.6K 0.12% 130
2021
Q1
$207K Buy
2,816
+115
+4% +$8.48K 0.13% 127
2020
Q4
$211K Buy
2,701
+155
+6% +$11.9K 0.13% 125
2020
Q3
$201 Buy
+2,546
New +$199K 0.08% 121

Other funds holding MRK

Smith Shellnut Wilson's MRK Position: Q3 2025 in Review

Smith Shellnut Wilson increased its Merck (MRK) stake by 16% in Q3 2025, buying an estimated $39.4K and bringing the position to 3,517 shares worth $295K. The position accounts for 0.11% of the portfolio, ranked #112.

Smith Shellnut Wilson first reported a position in MRK in Q3 2020 and has held it in 21 quarters since. The position peaked at $427K in Q1 2024. 3,309 funds tracked by Wall St. Rank hold MRK as of Q3 2025.

  • Smith Shellnut Wilson held 3,517 shares of Merck worth $295K as of Q3 2025.
  • Smith Shellnut Wilson bought 478 Merck shares in Q3 2025, an estimated $39.4K.
  • Merck made up 0.11% of Smith Shellnut Wilson's portfolio in Q3 2025, its #112 holding.
  • Smith Shellnut Wilson first reported a position in Merck in Q3 2020 and has held it in 21 quarters since.
  • Smith Shellnut Wilson's Merck position peaked at $427K in Q1 2024.
  • 3,309 funds tracked by Wall St. Rank held Merck as of Q3 2025.

Based on Smith Shellnut Wilson's 13F filing for Q3 2025, filed 27 Oct 2025.